Atrial fibrillation (AF) is a common arrhythmia which carries a
significant risk of stroke. Secondary prevention, particularly in the
acute phase of stroke with anti-thrombotic therapy, has not been
validated. The aim of this review is to evaluate the available evidence
on the use of antithrombotic therapy in patients with recent stroke who
have AF, and suggest a treatment algorithm for the various time points,
taking into account both the bleeding and thrombosis risks posed at each
stage
